<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01297400</url>
  </required_header>
  <id_info>
    <org_study_id>MW-III-BURN-2-001</org_study_id>
    <nct_id>NCT01297400</nct_id>
  </id_info>
  <brief_title>Phase 2, Open Label, Randomized, Active Controlled Pilot Study MW-III vs Silver Sulfadiazine Second Degree Thermal Burns</brief_title>
  <official_title>A Phase 2, Open-Label, Randomized, Active-Controlled Pilot Study of Investigational Drug, MW-III Versus Silvadene® Cream 1% (Silver Sulfadiazine) Topically Applied to Second-Degree Thermal Burns in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Skingenix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Skingenix, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to &quot;time to
      healing&quot; in second-degree thermal burns
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, randomized, active-controlled pilot study to evaluate the efficacy and
      safety profile of topical MW-III versus an active control (Silvadene® Cream 1% [Silver
      Sulfadiazine]) in the treatment of second-degree thermal burns in adults. Approximately 30
      subjects per treatment group will be enrolled and 60 subjects in total.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to healing, with a healed wound (wound healing) defined as ≥95% re-epithelialization of the target wound</measure>
    <time_frame>28 days Treatment Period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a healed wound.</measure>
    <time_frame>28 days Treatment Period and Follow-up Days 45, 60 and 90.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of re-epithelialization (%) at each scheduled study assessment</measure>
    <time_frame>28 days Treatment Period and Follow-up Days 45, 60 and 90.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scar scores at Days 28, 45, 60 and 90</measure>
    <time_frame>28 days Treatment Period and Follow-up Days 45, 60 and 90.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>Investigational Drug, MW-III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational Drug, MW-III</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Silvadene® Cream 1% [Silver Sulfadiazine]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MW-III</intervention_name>
    <description>Topical application, Twice a day</description>
    <arm_group_label>Investigational Drug, MW-III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Silver Sulfadiazine</intervention_name>
    <description>Topical Application, Twice a day</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults (≥18 years of age) on the day of signing the informed consent

          2. Diagnosed with a single second-degree thermal burn:

          3. Burn occurrence ≤24 hours prior to study entry

          4. Able and willing to give informed consent and comply with study procedures. In the
             case of a guardian, guardian must provide informed consent on behalf of the subject.

        Exclusion Criteria:

          1. Patients with the co-existence of full thickness (third-degree) burn wound

          2. Multiple second-degree thermal burns

          3. Circumferential burns or burns deemed high risk for developing compartment syndrome

          4. Target burn wound requiring surgical intervention, such as excision/grafting
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vicki Christodoulou, MS, JD</last_name>
    <phone>909-587-1650</phone>
    <phone_ext>1682</phone_ext>
    <email>vickic@skingenixusa.com</email>
  </overall_contact>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 14, 2011</study_first_submitted>
  <study_first_submitted_qc>February 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2011</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Burns, Partial Thickness Burns</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulfadiazine</mesh_term>
    <mesh_term>Silver Sulfadiazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

